Home
MMSupport.net unveils “Ask the Expert”, featuring Dr. James R. Berenson
MMSupport.net unveils “Ask the Expert”, featuring Multiple Myeloma physician and scientist, James R. Berenson, M.D. Ask the Expert is a free online web-forum where Myeloma and Bone Cancer specialist, Dr. James R. Berenson offers medical answers to questions surrounding quality of life and longevity issues for patients living with this rare form of cancer. Los Angeles, CA – MMSupport.net and the Institute for Myeloma and Bone Cancer Research are proud to announce the creation of “Ask the Expert”, a free online web-forum featuring Multiple Myeloma expert, Dr. James R. Berenson.
Read more...
Welcome to MMSupport!
This web site is dedicated to the memory of Chris Hollyer, and has been created for those of us with Multiple Myeloma, our caregivers and friends and families to use as a resource. The content is 100% contributed by members.
For many of us who suffer the incurable cancer called multiple myeloma,there was one person we turned to above all for information, guidance and wit, Chris Hollyer. MM took your life, Chris, but it will never take the patient and gentle spirit you left behind. - Ed Gorman
You're encouraged to contribute content about your experiences in order to help others learn by sharing your knowledge. You may use the "Contact Us" link to send your stories, news or comments. Thanks for visiting!
There's a new menu system. You can choose to participate in informal polls, read what others have contributed and print essential information by clicking on the appropriate menu selection.
Please use the search feature to find what you're looking for if you don't find it readily.
When registering, you don't have to use your full name if you don't wish to. Simply use your initials, first name and first letter of your surname or a nickname.
Stem cells make bone marrow cancer resistant to treatment
Public release date: 11-Jan-2008 Contact: Vanessa Wasta wastava@jhmi.edu 410-955-1287 Johns Hopkins Medical Institutions Scientists at the Johns Hopkins Kimmel Cancer Center say they have evidence that cancer stem cells for multiple myeloma share many properties with normal stem cells and have multiple ways of resisting chemotherapy and other treatments. A report on the evidence, published in the Jan. 1 issue of the journal Cancer Research, may explain why the disease is so persistent, the Johns Hopkins scientists say, and pave the way for treatments that overcome the cells’ drug resistance. Multiple myeloma affects bone marrow and bone tissue.
Read more...
Norepinephrine could hasten the progression of certain blood cancers
From an Ohio State University Press Release
http://researchnews.osu.edu/archive/yangvegf.htm
COLUMBUS, Ohio Researchers here have shown that in cell cultures, the stress hormone norepinephrine appears to promote the biochemical signals that stimulate certain tumor cells to grow and spread.
The finding, if verified, may suggest a way of slowing the progression and spread of some cancers enough so that conventional chemotherapeutic treatments would have a better chance to work. Eric Yang Ronald Glaser
Read more...
Researchers to Investigate Ways to Better Diagnose Autoimmune Disorders
(DALLAS, Oct. 17, 2007)Officials with Baylor Research Institute and the Mount Sinai School of Medicine announced today that the institutions are collaborating to develop therapeutic cancer vaccines for patients with lymphoma and myeloma, both cancers that affect the immune system. Additionally, the researchers will investigate ways to better diagnose autoimmune disorders such as arthritis and lupus.
Read more...
Velcade Before and After SCT for Newly Diagnosed
CHICAGO, June 3 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today reported on results presented by the University of Arkansas for Medical Sciences and the Center for Cancer Research and Biostatistics on Total Therapy 3 (TT3). TT3, a treatment for newly diagnosed multiple myeloma patients, includes a VELCADE based therapy prior to and as maintenance following stem cell transplantation. These results showed a significant improvement over previously reported results from Total Therapy 2 (TT2), a current standard of care, which did not include VELCADE. The data were presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. (Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )
Read more...
Research From Cleveland Clinic Provides New Insights Into Relapsed Or Refractory Multiple Myeloma
April 19, 2007 Research from Cleveland Clinic, U.S., provides new insights into human health. New research, "Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy," is the subject of a report. "Lenalidomide is active and well tolerated in relapsed and refractory multiple myeloma. We conducted a phase I/II trial of the combination of lenalidomide and chemotherapy to evaluate the safety and efficacy of the combination," scientists in the United States report.
Read more...
Mayo Clinic Cancer Center Researchers Find That a Byproduct of Mold Kills Multiple Myeloma
ROCHESTER, Minn. -- Mayo Clinic Cancer Center, March 7, 2007 (http://cancercenter.mayo.edu/) researchers have found that chaetocin, a by-product of a common wood mold, has promise as a new anti-myeloma agent. Results of their study are available online in the March 15 issue of Blood (http://bloodjournal.hematologylibrary.org/). "This research is only the beginning," says Keith Bible, M.D., Ph.D., oncologist and the study's primary investigator. "But we are very hopeful that chaetocin may some day provide needed help to our patients."
Read more...
Mayo Clinic Cancer Center -- Investigating the Measles Virus as a Tool to Kill Multiple Myeloma
ROCHESTER, Minn. -- Mayo Clinic Cancer Center has opened a new Phase I clinical trial testing an engineered measles virus against multiple myeloma, a cancer of the bone marrow that currently has no cure. This is the third of a series of molecular medicine studies in patients testing the potential of measles to kill cancer. "This is the beginning of a long but exciting process," says Angela Dispenzieri, M.D., hematologist and lead researcher on the multiple myeloma clinical trial in the measles virus investigation. "We are very hopeful that this will be a step toward helping our patients."
Read more...
A chemotherapy drug packs a one-two punch
Cancer can be wily, and those who treat the disease have amassed a wide array of weapons with which to fight it and kill tumors. Radiation therapy and various forms of chemotherapy were all thought to be separate but equal treatments. Now, however, new research is beginning to show that it’s not just killing the cancer cells that matter. How they’re killed may turn out to be just as important and could play a role in marshalling the body’s immune response.
Read more...
New Findings from the Mayo Clinic
Mayo Clinic Cancer Center -- individualizing treatment for multiple myeloma patients Defining how bortezomib works to help physicians find patients most likely to respond to the drug ORLANDO, Fla. -- Researchers at Mayo Clinic Cancer Center, in cooperation with industry partners, have, for the first time, identified tumor specific alterations in the cellular pathway by which the multiple myeloma drug bortezomib (Velcade) works, and they have identified nine new genetic mutations in cancer cells that should increase a patient's chance of responding to the agent.
Read more...
Circulating Cancer Cells Indicate Worse Outcomes Following Autologous Stem Cell Transplant
Circulating Cancer Cells Indicate Worse Outcomes Following Autologous Stem Cell Transplantation in Multiple Myeloma According to an article recently published in the journal Blood, the presence of cancer cells circulating in the blood is associated with a less favorable prognosis following an autologous stem cell transplant in patients with multiple myeloma.
Read more...
Ten Things to Do
by Chris Hollyer
1.Take a deep breath. You have just been diagnosed with something you probably have never heard of, a cancer of the bone marrow. Multiple Myeloma is a plasma cell cancer. Plasma cells are produced in the bone marrow. Your initial response is to panic, worry, question yourself - why me? DONT. Instead, take a deep breath and stay calm. This is NOT the end of the world as you know it. MM is as yet incurable, but HIGHLY treatable.
Read more...
Multiple Myeloma, the End Phase
We have noticed over the past couple of years that people find our site, www.mmsupport.net using search phrases like Final Days of Myeloma" and "What's It Like To Die From MM?" Not the easiest of topics to discuss, but it is something we should try to cover.
Read more...
To SCT or not?
by Chris Hollyer
Well, youve been diagnosed with Multiple Myeloma: probably never heard of it before - few of us had. Now your doctor is talking about High Dose Chemotherapy and a Stem Cell Transplant. Probably never heard of that either. What are you to do? Welcome to the ongoing conundrum that is myeloma treatment.
Read more...
MRI of Bone Marrow Predicts Outcomes of Multiple Myeloma
According to a recent article published in the Annals of Oncology, results from magnetic resonance imaging (MRI) of bone marrow in patients with untreated multiple myeloma helps to predict survival duration. These results may contribute to evaluation and treatment decisions of patients with this disease.
Read more...
|
Tax Deductible DonationPlease support this site and online support for health challenges of all kinds, which are provided by the Online Patient Empowerment Project, a 501(c)(3) Corporation.
Mailing ListsHave you subscribed to the MMA interactive mailing list? Please click HERE to subscribe. Once subscribed, you can choose a daily digest version, real time delivery and you'll have access to the list archives. To join the ACOR list, please click HERE.
StatisticsVisitors: 637213

|